The BRD4 inhibitors JQ1 and MS417 improve the growth-suppressive effect mediated by AKTi, and the BRD4/FOXO3a/CDK6 axis passivates AKT inhibition in luminal breast cancer [170]. Here, AKT1 is linked to breast cancer.